Navigation Links
Cumberland Pharmaceuticals Reports 24% Increase in Net Revenue With Full Year 2009 Financial Results
Date:3/10/2010

4,137,942 Amortization of product license right 686,904 686,904 686,905 Other 106,776 104,209 96,524 ------- ------- ------ Total costs and expenses 37,760,643 27,792,939 21,338,271 ---------- ---------- ---------- Operating income 5,776,635 7,282,221 6,725,318 Interest income 79,363 241,282 382,919 Interest expense (772,927) (213,303) (639,590) -------- -------- -------- Income before income taxes 5,083,071 7,310,200 6,468,647 Income tax expense (2,024,192) (2,543,951) (2,424,261) ---------- ---------- ---------- Net income 3,058,879 4,766,249 4,044,386 Net loss at subsidiary attributable to noncontrolling interests 32,536 - - Net income attributable to common shareholders $3,091,415 $4,766,249 $4,044,386 ========== ========== ========== Earnings per share attributable to common shareholders - Basic $0.22 $0.47 $0.40 - Diluted $0.17 $0.29 $0.24 Weighted-average shares outstanding - Basic 14,199,479 10,142,807 10,032,083 - Diluted 18,234,171 16,539,662 16,581,902 CUMBERLAND PHARMACEUTICALS INC. CONSOLIDATED STATEMENTS OF CASH FLOWS YEARS ENDED DECEMBER 31, 2009, 2008 AND 2007
'/>"/>
SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
2. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
3. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)... , September 12, 2014 ... Market by Application [Beverages (Alcoholic, CSD, Sports & Energy ... Pet Food, Meat & Seafood)], by Material (Aluminum ... by MarketsandMarkets, defines and segments the Food & ... of each application in terms of volumes and ...
(Date:9/12/2014)... , Sept. 12, 2014 /PRNewswire-iReach/ -- 9 th ... 22-24, 2014 – Bethesda, MD ... http://www.fdanews.com/9thInspectionsSummitEarlyBird   Photo - http://photos.prnewswire.com/prnh/20140912/145652 ... for the next inspection than to get a glimpse ... during and after an inspection. Come to ...
(Date:9/12/2014)... 12, 2014 Research and Markets ... "Global Medical Technologies Market 2014-2018" report to ... a collective term for software solutions, medical devices, ... health. The Global Medical Technologies market covers active ... In vitro diagnostics technology, dental technology, electromechanical medical ...
Breaking Medicine Technology:Food & Beverage Metal Cans Market Worth $49.20 Billion by 2019 2Food & Beverage Metal Cans Market Worth $49.20 Billion by 2019 3Food & Beverage Metal Cans Market Worth $49.20 Billion by 2019 4FDAnews Announces: Early Bird Registration Discount Ends Sept.19 for 9th Annual Inspections Summit, Oct. 22-24, 2014 2FDAnews Announces: Early Bird Registration Discount Ends Sept.19 for 9th Annual Inspections Summit, Oct. 22-24, 2014 3Global Medical Technologies Market 2014-2018: Key Vendors are GE, Johnson & Johnson, Medtronic, Roche and Siemens 2Global Medical Technologies Market 2014-2018: Key Vendors are GE, Johnson & Johnson, Medtronic, Roche and Siemens 3
... and CAMPBELL, Calif. , May ... sophisticated risk characterization and personalized therapy guidelines for ... of advanced tests, offering an accompanying nutrition program, ... Director stated:  "With appropriate risk characterization and treatment, ...
... May 25 The U.S. Food and Drug Administration approved Lumizyme (alglucosidase ... a rare genetic disorder. , , ... http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) , , , ... an estimated 1 in every 40,000 to 300,000 births. Its primary symptom is ...
Cached Medicine Technology:Health Network Laboratories (HNL) Enters Into License Agreement With Hunter Laboratories to Provide HunterHeart Cardiovascular Disease Management Program. 2FDA Approves New Treatment for Late-Onset Pompe Disease 2FDA Approves New Treatment for Late-Onset Pompe Disease 3
(Date:9/15/2014)... (PRWEB) September 15, 2014 (PRWEB) September 15, 2014 ... not; what the startup business requirements are in each ... new business. , Speakers include industry professionals, such as ... Center in Oakland,CA and cannabis business consultant ... who are already successfully running legal marijuana businesses all ...
(Date:9/14/2014)... Petersburg, FL (PRWEB) September 15, 2014 Skin ... external factors like sun damage and not moisturizing properly. However, ... if skin has been cared for. , Two main reasons ... 2) Loss of hyaluronic acid in the skin , During ... and both of these are responsible for important moisture retention ...
(Date:9/14/2014)... Government support for safe patient handling has ... market , The global patient handling equipment market ... five years. The growth of this market is ... increasing lifestyle diseases such as diabetes and Cardiovascular ... market is driven by factors such as government ...
(Date:9/14/2014)... (HealthDay News) -- Getting enough sleep each night may mean you,re ... a new study suggests. The study included more than 3,700 ... an average of seven years. Those who slept less than ... more likely to have extended absences from work due to illness, ... off from work due to sickness were those who slept between ...
(Date:9/14/2014)... A new DePuy Pinnacle hip lawsuit has been filed by ... Franklin County, Ohio man who underwent hip surgery to remove ... filed against Johnson & Johnson and its subsidiary, DePuy Orthopedics, ... when the Pinnacle Hip device was surgically implanted in his ... hip implant lawsuit , the man underwent a revision surgery ...
Breaking Medicine News(10 mins):Health News:How to Start And Run a Successful Legal Marijuana Business 2Health News:2 Reasons Skin Becomes Dryer with Age and What To Do About It, From Sublime Beauty® 2Health News:2 Reasons Skin Becomes Dryer with Age and What To Do About It, From Sublime Beauty® 3Health News:10.7% CAGR For Patient Handling Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 2Health News:10.7% CAGR For Patient Handling Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 3Health News:10.7% CAGR For Patient Handling Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 4Health News:A Good Night's Sleep May Mean a Good Day's Work 2Health News:Wright & Schulte LLC Files Another DePuy Pinnacle Hip Lawsuit Purporteding Risky Revision Surgery Needed Due To Failure of Metal-on-Metal Hip Replacement 2Health News:Wright & Schulte LLC Files Another DePuy Pinnacle Hip Lawsuit Purporteding Risky Revision Surgery Needed Due To Failure of Metal-on-Metal Hip Replacement 3Health News:Wright & Schulte LLC Files Another DePuy Pinnacle Hip Lawsuit Purporteding Risky Revision Surgery Needed Due To Failure of Metal-on-Metal Hip Replacement 4Health News:Wright & Schulte LLC Files Another DePuy Pinnacle Hip Lawsuit Purporteding Risky Revision Surgery Needed Due To Failure of Metal-on-Metal Hip Replacement 5
... WHAT: 211 San Diego executives will highlight key initiatives the, ... nationwide service, discuss the ... times of need, and honor community leaders for their support and, ... Journey event. 211 San Diego also will, ...
... 11 The Ensign Group, Inc. (Nasdaq: ... Ensign(TM) group of skilled nursing, rehabilitative care services ... will participate in the Eighth Annual JMP Securities ... Ritz-Carlton in San Francisco. (Logo: http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO )Christopher ...
... Reiterates Going Concern Opinion to Comply with NASDAQ ... Encorium Group, Inc. (Nasdaq: ENCO ... (CRO) that provides design, development, and management capabilities ... of the world,s leading pharmaceutical companies, today announced ...
... - The Westaim Corporation announced today that for the quarter ended ... or 3 cents per share, on revenues of $5.2 million compared ... share, on revenues of $5.2 million in the previous year. The ... was $2.3 million compared to income of $3.2 million for the ...
... This release is available in French . ... immunity, men may not have been dealt an equal hand. ... Institute of the McGill University Health Centre and McGill University, ... men. In fact, the production of estrogen by females could ...
... Trust Incorporated (NYSE: HR ) today announced its ... 2009. This dividend, in the amount of $0.385 per ... record on May 22, 2009. The total dividend of ... operations determined in accordance with GAAP. The Company,s cash ...
Cached Medicine News:Health News:211 San Diego Provides Support to San Diegans in Times of Crisis 2Health News:The Ensign Group to Present at the Eighth Annual JMP Securities Research Conference on May 19th 2Health News:The Ensign Group to Present at the Eighth Annual JMP Securities Research Conference on May 19th 3Health News:Encorium Group Enters into Non-Binding Letters of Intent 2Health News:Encorium Group Enters into Non-Binding Letters of Intent 3Health News:Encorium Group Enters into Non-Binding Letters of Intent 4Health News:Encorium Group Enters into Non-Binding Letters of Intent 5Health News:Westaim announces 2009 first quarter results 2Health News:Westaim announces 2009 first quarter results 3Health News:Equality of the sexes? Not always when it comes to biology 2Health News:Healthcare Realty Trust Announces First Quarter Dividend 2Health News:Healthcare Realty Trust Announces First Quarter Dividend 3Health News:Healthcare Realty Trust Announces First Quarter Dividend 4
Free Estriol (E3) RIA Reproductive Hormones 024-IDC-2000...
Prolactin EIA Reproductive Markers 025-BC-1037...
... (17aOHP) is produced by both the ... has relatively little progestational activity, it ... it is the,immediate precursor to 11-desoxycortisol ... 21-hydroxylation of 17aOHP,measurement of 17aOHP is ...
FSH EIA Reproductive Markers 025-BC-1029 Follicle Stimulating Hormone...
Medicine Products: